|
13 Sep 2025 |
Divi's Laboratories
|
Consensus Share Price Target
|
6026.50 |
6362.79 |
- |
5.58 |
hold
|
|
|
|
|
08 Nov 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
6026.50
|
3893.00
|
3414.55
(76.49%)
|
Target met |
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) Q2FY23 performance was sharply below our estimates. Consolidated revenue fell 6.7% YoY to Rs18.5bn (I-Sec: Rs22.9bn), EBITDA margin slipped 770bps YoY to 33.5% (I-Sec: 41.2%) and adjusted PAT declined 18.6% YoY to Rs4.9bn (I-Sec: Rs6.2bn).
|
|
03 Oct 2022
|
Divi's Laboratories
|
Ashika Research
|
6026.50
|
4110.00
|
3726.85
(61.70%)
|
|
Buy
|
|
|
|
|
25 Aug 2022
|
Divi's Laboratories
|
Geojit BNP Paribas
|
6026.50
|
4006.00
|
3587.50
(67.99%)
|
|
Buy
|
|
|
|
|
16 Aug 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
6026.50
|
4173.00
|
3726.20
(61.73%)
|
|
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) Q1FY23 performance was a mixed bag with revenue ahead of our estimates while margin was lower.
|
|
15 Aug 2022
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6026.50
|
4140.00
|
3732.00
(61.48%)
|
|
Accumulate
|
|
|
|
|
13 Aug 2022
|
Divi's Laboratories
|
BOB Capital Markets Ltd.
|
6026.50
|
4250.00
|
3726.20
(61.73%)
|
|
Hold
|
|
|
Q1 revenue broadly in line with consensus at Rs 22.5bn (+15% YoY/-10% QoQ), but EBITDA 10% below
|
|
12 Aug 2022
|
Divi's Laboratories
|
ICICI Direct
|
6026.50
|
4315.00
|
3726.20
(61.73%)
|
|
Buy
|
|
|
|
|
26 May 2022
|
Divi's Laboratories
|
SMC online
|
6026.50
|
|
3514.70
(71.47%)
|
|
Results Update
|
|
|
|
|
24 May 2022
|
Divi's Laboratories
|
ICICI Direct
|
6026.50
|
4655.00
|
3661.70
(64.58%)
|
|
Buy
|
|
|
|
|
24 May 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
6026.50
|
4361.00
|
3897.90
(54.61%)
|
|
Accumulate
|
|
|
The strong growth was led by the custom synthesis division most likely due to higher than expected revenues from Molnupiravir. API segment continues its weak performance due to intense pricing pressures.
|